Related Experiment Video
Updated: May 17, 2026

10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
[The natural peptide geroprotector antiarhythmic action].
Advances in Gerontology = Uspekhi Gerontologii
|November 8, 2012
Summary
The peptide geroprotector Slavinorm, derived from calf aorta extract, demonstrated efficacy in experimental models of hypertension and arrhythmia. This study suggests Slavinorm
Area of Science:
- Gerontology and Cardiovascular Pharmacology
- Peptide Therapeutics
- Vascular Biology
Context:
- Hypertension and cardiac arrhythmia are prevalent age-related cardiovascular pathologies.
- Vascular dysfunction significantly contributes to age-related diseases.
- Calf aorta extract-derived peptides are explored for therapeutic potential.
Purpose:
- To investigate the biological activity of the peptide geroprotector Slavinorm.
- To evaluate Slavinorm's effects on experimental models of hypertension and chloride-calcium arrhythmia.
- To assess Slavinorm's potential in treating age-related vascular pathologies.
Summary:
- Slavinorm administration in a rat model of pituitrin-induced arrhythmia normalized blood pressure, body weight, and organ weights, alleviating hypertension symptoms.
- In a rat model of chloride-calcium arrhythmia, Slavinorm administration predicted and mitigated arrhythmia development.
- These findings indicate Slavinorm's potential therapeutic value for age-related conditions involving impaired vascular function.
Impact:
- Provides evidence for Slavinorm as a potential therapeutic agent for age-related cardiovascular diseases.
- Highlights the role of peptide geroprotectors in managing hypertension and arrhythmia.
- Supports further research into Slavinorm for treating pathologies linked to vascular impairment.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
G-Protein Gated Ion Channels
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory organs,...
Sensory organs,...
